ARCHIVES

FDA Approves Gemzar For Ovarian Cancer, Contradicting ODAC Recommendation; Continues Agency Trend to Recognize Progression-Free Survival As An Endpoint.

This article is from The Cancer Letter archive.

Vol. 32 No. 28 | July 21, 2006

Download PDF Visit The Full Archive

Related Articles

Talactoferrin Second-Line Therapy Increases Survival In Stage IIIB/IV

October 28, 2011

DCPC Board To hear To Hear Concept for Contract to Develop Program For Heavy Smokers

January 11, 1985

NCI Tells CCOPs To Slow Patient Accrual To Clinical Trials, Prepare For Budget Cuts.

May 12, 2006

ACCC Presentations On Care In Community

March 27, 1981

In Congress: Senate Committee Provides Increase To DOD Program

August 1, 1997

Geography Still An Issue For Centers: Durant Asks Is It “Holy Water” or Money

April 26, 1985